Last reviewed · How we verify
NCT04729452
Characterisation of the Immune Response to SARS-CoV-2 / COVID-19
trial testing blood test in Covid19 in 160 participants. Completed in 1 December 2023.
1 October 2023
Quick facts
| Lead sponsor | Cwm Taf University Health Board (NHS) |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 160 |
| Start date | 1 June 2020 |
| Primary completion | 1 October 2023 |
| Estimated completion | 1 December 2023 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- blood test — full drug profile →
Conditions studied
- Covid19 — all drugs for Covid19 →
Sponsor
Cwm Taf University Health Board (NHS)
Who can join
18 and older, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Emerging clinical details of the current SARS-CoV-2 pandemic have illustrated that there are multiple clinical presentations and outcomes of this viral infection. People with an infection have been reported to have a spectrum of disease from severe acute respiratory distress requiring ventilation, to mild respiratory or gastrointestinal symptoms and asymptomatic presentations. Mechanisms explaining the heterogeneity of host response to infection are yet to be characterised. The aim of this project is to understand the host immune response to infection with SARS-CoV-2 over time in convalescent adults, including acquired immune responses, circulating levels of immune signalling molecules, gene expression profiling in peripheral blood and to identify host genetic variants associated with disease progressions or severity. Participants will be healthcare workers who had a diagnosis of COVID-19 (confirmed by positive RT-PCR assay) more than 28 days ago and have recovered and are employed by Cwm Taf Morgannwg University health board. Samples will be processed and analysed to explore immunological, host genetic factors and virological factors that explain pathogenesis and predict outcomes of infection.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
HLA A*24:02-restricted T cell receptors cross-recognize bacterial and preproinsulin peptides in type 1 diabetes.
Dolton G, Bulek A, Wall A, Thomas H, et al · · 2024 · cited 7× · PMID 39286976 · DOI 10.1172/jci164535
Verify or expand the search:
- PubMed search for NCT04729452
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of blood test
Trials testing the same drug.
- NCT06971289 — Development and Characterization of Functional Assays for the Analysis of Inflammation Signaling Pathways · not yet recruiting
- NCT06983197 — Iatrogenic Deficiencies in ICU Patients With Prolonged Continuous Renal Replacement Therapy · not yet recruiting
- NCT06375889 — Platelet Activation in Delayed Cerebral Ischemia Secondary to Aneurysmal Subarachnoid Hemorrhage · completed
- NCT05901207 — Diagnostic and Prognostic Biomarkers for IgG4-related Disease. · unknown
- NCT06212505 — EVALUATION of the OVERALL HAEMOSTATIC CAPACITY of MIM8 with GLOBAL HAEMOSTASIS ASSAYS and FIBRIN CLOT ULTRASTRUCTURE · completed
Other recruiting trials for Covid19
Currently open trials in the same condition.
- NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
- NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
- NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
- NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
- NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting
Other Cwm Taf University Health Board (NHS) trials
Trials by the same sponsor.
- NCT05968209 — The Impact of Probiotic Supplementation on General Well Being · NA · completed
- NCT05645081 — Extracellular Vesicles and Dysregulated Coagulation in the Prediction of Stroke · recruiting
- NCT05171998 — Characterisation of the Immune Response to SARS-CoV-2 Infection / COVID-19 in Type 1 Diabetes · completed
- NCT05391035 — The Antibiotic Guardian Study- Clinical Evaluation of a Novel, Rapid Diagnostic for Gonorrhoea and Mycoplasma Infections · completed
- NCT05186792 — Mycoplasma Species and the Genitourinary System · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04729452 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Cwm Taf University Health Board (NHS)
- Last refreshed: 17 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04729452.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing